Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia
Asia-Pacific Journal of Clinical Oncology · 15.05.2026
DOI: 10.1111/ajco.70123 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, online erschienen am 15.05.2026. Verfasst von Nicholas Zdenkowski und 6 weiteren Autor:innen. Beteiligte Einrichtung: Breast Cancer Trials, University of Newcastle, New South Wales, Australia. Die Arbeit nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly Australia & Novartis Pharmaceuticals Australia.
Abstract (Originalsprache)
Breast cancer is the most common cancer among Australian women, with early‐stage disease (Stages I, II, and III) representing the majority of cases. Advances in screening, diagnosis, and systemic therapies, including chemotherapy, endocrine therapy, targeted agents, and immunotherapy, have markedly improved survival rates. This review synthesizes recent developments in systemic therapy for early breast cancer, with a focus on Australian data and practice patterns. We explore subtype‐specific management strategies for estrogen receptor‐positive (ER+)/HER2‐negative, HER2‐positive, and triple‐negative breast cancer (TNBC). For ER+/HER2− early breast cancer, the utility of genomic assays such as Oncotype DX, PAM50, and MammaPrint is discussed, with a focus on chemotherapy selection and the role of CDK4/6 inhibitors, and the role of extended endocrine therapy and adjuvant zoledronic acid. In HER2‐positive breast cancer, we examine neoadjuvant therapy with dual HER2 blockade (trastuzumab and pertuzumab), personalized regimens that minimize cardiotoxicity, and the potential of antibody‐drug conjugates. For TNBC, the growing role of immunotherapy, dose‐dense regimens, and adjuvant capecitabine is reviewed, with a focus on olaparib in BRCA‐mutated cases. This review also addresses special populations, including BRCA mutation carriers and premenopausal women, and looks at future trends in systemic therapy, including novel agents, biomarker‐driven approaches, and treatment de‐escalation strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Breast Cancer Trials, University of Newcastle, New South Wales, Australia.
- Hunter Valley Oncology, Gateshead, Australia.
- Department of Medical Oncology, St Vincent's Hospital Sydney, University of New South Wales, Sydney, New South Wales, Australia.
- Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia.
- Fiona Stanley Hospital, Perth, Western Australia, Australia.
- University of Western Australia, Perth, Western Australia, Australia.
Förderung
- Eli Lilly Australia & Novartis Pharmaceuticals Australia
Zitieren
APA
Zdenkowski, N., Dear, R., Kumar, S., Martin, H., Sabanathan, D., Luen, S. J., & Yeo, B. (2026). Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.70123
Vancouver
Zdenkowski N, Dear R, Kumar S, Martin H, Sabanathan D, Luen SJ, et al. Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia. Asia-Pacific Journal of Clinical Oncology. 2026. doi:10.1111/ajco.70123
BibTeX
@article{Zdenkowski2026,
author = {Zdenkowski, Nicholas and Dear, Rachel and Kumar, Sanjeev and Martin, Hilary and Sabanathan, Dhanusha and Luen, Stephen J and Yeo, Belinda},
title = {Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2026},
doi = {10.1111/ajco.70123}
}
EUVIMED